1Brigham and Women's Hospital, Boston, MA [email protected]
2Bayer US, Boston, MA
3Indiana University School of Medicine, Indianapolis, IN
Views in this letter do not represent those of the authors’ employers or affiliates.
Dr. Singh reports having received consulting fees from GSK, Bayer HealthCare Pharmaceuticals, Zydus, the Centers for Disease Control and Prevention, and Nephrology Times. Dr. Farag reports being employed at Bayer US. Dr. Agarwal reports having received consulting fees and nonfinancial support for travel from Bayer HealthCare Pharmaceuticals, Akebia Therapeutics, AstraZeneca, Boehringer Ingelheim, Eli Lilly, and Vifor Pharma, being a member of data and safety monitoring committees for Chinook and Vertex, having served as associate editor of the American Journal of Nephrology and Nephrology Dialysis Transplantation, having been an author for UpToDate, and having received research grants from the U.S. Department of Veterans Affairs and the National Institutes of Health. No other potential conflict of interest relevant to this letter was reported.
